Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALRN Aileron Therapeutics		$2.52	$1.61 ▼ $4.40	$45.72M	2.24	82,980 shs	63,385 shs
CYBN Cybin	$7.17 -5.7%	$7.93	$4.81 ▼ $13.88	$169.14M	0.68	314,932 shs	468,290 shs
LYEL Lyell Immunopharma	$10.76 -0.6%	$10.31	$7.65 ▼ $32.40	$166.32M	-0.19	85,234 shs	23,106 shs
RAPT Rapt Therapeutics	$11.25 +6.1%	$9.60	$5.67 ▼ $26.56	$186.08M	0.01	113,010 shs	47,572 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALRN Aileron Therapeutics	0.00%	0.00%	0.00%	0.00%	+2.43%
CYBN Cybin	-0.39%	+1.88%	+1.74%	+15.85%	+1,959.62%
LYEL Lyell Immunopharma	+2.46%	-2.26%	+12.00%	+34.80%	-60.47%
RAPT Rapt Therapeutics	-2.75%	+6.11%	+21.56%	+63.80%	-46.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALRN Aileron Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYBN Cybin	2.0019 of 5 stars	3.6	0.0	0.0	0.0	0.6	0.8	1.3
LYEL Lyell Immunopharma	3.2872 of 5 stars	2.8	5.0	0.0	0.0	1.0	4.2	1.3
RAPT Rapt Therapeutics	4.5874 of 5 stars	4.3	3.0	0.0	4.2	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALRN Aileron Therapeutics	0.00	N/A	N/A	N/A
CYBN Cybin	3.25	Buy	$85.00	1,085.50% Upside
LYEL Lyell Immunopharma	1.50	Reduce	$15.00	39.41% Upside
RAPT Rapt Therapeutics	2.57	Moderate Buy	$21.57	91.75% Upside

Current Analyst Ratings Breakdown

Latest ALRN, LYEL, CYBN, and RAPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/8/2025	RAPT Rapt Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $38.00
7/30/2025	RAPT Rapt Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$14.00
7/22/2025	RAPT Rapt Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$31.00
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00
7/8/2025	CYBN Cybin	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$73.00 ➝ $70.00
6/24/2025	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00
5/22/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
5/22/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$48.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALRN Aileron Therapeutics	N/A	N/A	N/A	N/A	$1.41 per share	N/A
CYBN Cybin	N/A	N/A	N/A	N/A	$10.83 per share	N/A
LYEL Lyell Immunopharma	$60K	2,771.96	N/A	N/A	$26.21 per share	0.41
RAPT Rapt Therapeutics	$1.53M	121.62	N/A	N/A	$9.94 per share	1.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALRN Aileron Therapeutics	-$15.73M	-$3.12	0.00	N/A	N/A	N/A	-74.08%	-27.93%	N/A
CYBN Cybin	-$57.88M	-$3.88	N/A	N/A	N/A	N/A	-37.58%	-36.59%	N/A
LYEL Lyell Immunopharma	-$342.99M	-$24.29	N/A	N/A	N/A	-552,328.31%	-79.53%	-64.56%	N/A
RAPT Rapt Therapeutics	-$129.87M	-$14.17	N/A	N/A	N/A	N/A	-67.92%	-59.59%	N/A

Latest ALRN, LYEL, CYBN, and RAPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	LYEL Lyell Immunopharma	-$3.80	-$2.89	+$0.91	-$2.89	$0.00 million	$0.01 million
8/7/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.61	-$0.65	-$0.04	-$0.65	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALRN Aileron Therapeutics	N/A	N/A	N/A	N/A	N/A
CYBN Cybin	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALRN Aileron Therapeutics	N/A	3.30	3.30
CYBN Cybin	N/A	24.24	24.24
LYEL Lyell Immunopharma	N/A	7.49	7.49
RAPT Rapt Therapeutics	N/A	13.25	21.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALRN Aileron Therapeutics	90.89%
CYBN Cybin	17.94%
LYEL Lyell Immunopharma	66.05%
RAPT Rapt Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
ALRN Aileron Therapeutics	5.10%
CYBN Cybin	15.00%
LYEL Lyell Immunopharma	22.30%
RAPT Rapt Therapeutics	2.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALRN Aileron Therapeutics	9	21.67 million	20.56 million	Not Optionable
CYBN Cybin	50	23.59 million	17.96 million	Not Optionable
LYEL Lyell Immunopharma	270	15.46 million	12.01 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	16.15 million	Optionable

ALRN, LYEL, CYBN, and RAPT Headlines

Recent News About These Companies

Rapt Therapeutics price target raised to $9 from $8 at UBS

August 12 at 6:58 PM | msn.com

Rapt Therapeutics (RAPT)'s Technical Outlook is Bright After Key Golden Cross

August 12 at 10:55 AM | zacks.com

HC Wainwright Issues Optimistic Forecast for RAPT Earnings

August 12 at 2:45 AM | americanbankingnews.com

Rapt Therapeutics (NASDAQ:RAPT) Stock Rating Lowered by Wall Street Zen

August 11 at 3:51 AM | americanbankingnews.com

HC Wainwright Issues Positive Forecast for RAPT Earnings

August 11 at 2:43 AM | marketbeat.com

Rapt Therapeutics (NASDAQ:RAPT) Rating Lowered to Sell at Wall Street Zen

August 10, 2025 | marketbeat.com

RAPT Therapeutics Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Rapt Therapeutics (RAPT) Expected to Announce Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade

August 1, 2025 | zacks.com

Rapt Therapeutics (NASDAQ:RAPT) Upgraded by JPMorgan Chase & Co. to "Neutral" Rating

July 31, 2025 | marketbeat.com

RAPT Therapeutics Unveils Plans for RPT904 Development

July 30, 2025 | theglobeandmail.com

Rapt Therapeutics upgraded to Neutral from Underweight at JPMorgan

July 30, 2025 | msn.com

JP Morgan Upgrades RAPT Therapeutics (RAPT)

July 30, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Raised to Hold at Wall Street Zen

July 26, 2025 | marketbeat.com

Q2 Earnings Forecast for RAPT Issued By Lifesci Capital

July 25, 2025 | marketbeat.com

LifeSci Capital Initiates Coverage of RAPT Therapeutics (RAPT) with Outperform Recommendation

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Coverage Initiated by Analysts at Lifesci Capital

July 23, 2025 | marketbeat.com

Rapt Therapeutics initiated with an Outperform at LifeSci Capital

July 23, 2025 | msn.com

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of "Hold" from Analysts

July 23, 2025 | marketbeat.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | msn.com

Rapt Therapeutics (RAPT) Upgraded to Strong Buy: Here's Why

July 15, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALRN, LYEL, CYBN, and RAPT Company Descriptions

Aileron Therapeutics NASDAQ:ALRN

Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.

Cybin NYSE:CYBN

$7.17 -0.43 (-5.66%)

Closing price 04:00 PM Eastern

Extended Trading

$7.16 0.00 (-0.07%)

As of 04:30 PM Eastern

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Lyell Immunopharma NASDAQ:LYEL

$10.76 -0.07 (-0.65%)

Closing price 04:00 PM Eastern

Extended Trading

$10.70 -0.06 (-0.56%)

As of 04:04 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Rapt Therapeutics NASDAQ:RAPT

$11.25 +0.65 (+6.13%)

Closing price 04:00 PM Eastern

Extended Trading

$11.24 -0.01 (-0.09%)

As of 04:10 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time